Cited by 309Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology ResearchEpilepsy research and treatment

Defective GABAergic Neurotransmission and Pharmacological Rescue of Neuronal Hyperexcitability in the Amygdala in a Mouse Model of Fragile X Syndrome

Open access
Olmos-Serrano, J. L., Paluszkiewicz, S. M., Martin, B. S., Kaufmann, W. E., Corbin, J. G., Huntsman, M. M.·2010·Journal of Neuroscience

Abstract

Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by variable cognitive impairment and behavioral disturbances such as exaggerated fear, anxiety and gaze avoidance. Consistent with this, findings from human brain imaging studies suggest dysfunction of the amygdala. Underlying alterations in amygdala synaptic function in the Fmr1 knock-out (KO) mouse model of FXS, however, remain largely unexplored. Utilizing a combination of approaches, we uncover profound alterations in inhibitory neurotransmission in the amygdala of Fmr1 KO mice. We demonstrate a dramatic reduction in the frequency and amplitude of phasic IPSCs, tonic inhibitory currents, as well as in the number of inhibitory synapses in Fmr1 KO mice. Furthermore, we observe significant alterations in GABA availability, both intracellularly and at the synaptic cleft. Together, these findings identify abnormalities in basal and action potential-dependent inhibitory neurotransmission. Additionally, we reveal a significant neuronal hyperexcitability in principal neurons of the amygdala in Fmr1 KO mice, which is strikingly rescued by pharmacological augmentation of tonic inhibitory tone using the GABA agonist gaboxadol (THIP). Thus, our study reveals relevant inhibitory synaptic abnormalities in the amygdala in the Fmr1 KO brain and supports the notion that pharmacological approaches targeting the GABAergic system may be a viable therapeutic approach toward correcting amygdala-based symptoms in FXS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.1714-10.2010

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pharmacological approaches targeting the GABAergic system have been successfully exploited to correct amygdala-based symptoms in fragile X syndrome.

    “Pharmacological approaches targeting the GABAergic system have been successfully exploited to correct amygdala-based symptoms in FXS (114).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 62 · Cited by 309

Authors
Olmos-Serrano, J. L., Paluszkiewicz, S. M., Martin, B. S., Kaufmann, W. E., Corbin, J. G., & Huntsman, M. M.
Affiliations
  • Children's National (US)
  • Kennedy Krieger Institute (US)
Venue
Journal of Neuroscience
Published
2010-07-21
Volume
30
Issue
29
Pages
9929-9938
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2078544102
Cited by
309
References
62
Citations by year
2026: 8 · 2025: 9 · 2024: 9 · 2023: 12 · 2022: 22 · 2021: 16 · 2020: 17 · 2019: 14 · 2018: 15 · 2017: 25 · 2016: 22 · 2015: 24 · 2014: 29 · 2013: 29 · 2012: 28
FWCI
15.63
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Canadian Institutes of Health Research (181393)
  • National Institute on Drug Abuse (DA020140, R01DA020140)
  • National Institute of Neurological Disorders and Stroke (NS-053719, R01NS053719, R56NS053719)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30HD40677, P30HD040677)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
Keywords
fragile X syndrome, Fmr1 knockout mice, amygdala, GABAergic neurotransmission, synaptic inhibition, neuronal hyperexcitability, inhibitory postsynaptic currents, gaboxadol, THIP, FMRP, anxiety, fear, pharmacological rescue
MeSH terms
Amygdala, Animals, Disease Models, Animal, Evoked Potentials, Fragile X Syndrome, gamma-Aminobutyric Acid, Glutamate Decarboxylase, Interneurons, Isoxazoles, Male, Neural Inhibition, Synaptic Transmission, Neurons, Mice, Knockout, Patch-Clamp Techniques, GABA Agonists, Mice, Fragile X Messenger Ribonucleoprotein 1, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review